Embed
Email

Biochemistry of Lithium

Document Sample

Shared by: Jun Wang
Categories
Tags
Stats
views:
13
posted:
2/21/2012
language:
pages:
18
+

PHM142 Fall 2011

Instructor: Henderson









Biochemistry of Lithium

Lauren Filice (lauren.filice@mail.utoronto.ca)

Jennifer Jin (jennifer.jin@utoronto.ca) Course: PHM142

Marina Mikhail (marina_mikhail@hotmail.com) Instructor: Dr. Jeffrey Henderson

Clarisse Nyirazuba (clarisse.nyirazuba@utoronto.com) Sign-up date: Nov. 28, 2011

+

Outline



 Lithium ion



 Pharmacological use



 Psychiatric disorders



 Mechanisms of action



 Toxicity



 Drug interactions



 Summary

+

What is lithium?



 Lithium (Li+) is a monovalent cation



 Soft, low density alkali metal



 Lithium salts have been used as medication for over 60 years



 Pharmacological effects were discovered in 1949 by John Cade



 Mood-stabilizing drug used in a variety of neuropsychiatric

disorders



 Modifys intracellular signal transduction pathways in the CNS

+

Pharmacological use





 Drugs: lithium carbonate (Li2CO3), lithium citrate (Li3C6H5O7 - shown)



 Brand names: Carbolith, Duralith, Lithane, Lithmax



 Treatment of bipolar disorder, depression, chronic cluster headache



 Anti-suicidal and neuro-protective effects



 Well-absorbed, widely distributed in most tissues, crosses blood-

brain barrier



 Exhibits narrow therapeutic window with serious toxic side effects



 Numerous drug and food interactions



 Controversial, but still generally considered effective as a

psychiatric drug Image from Wikipedia

+

Psychiatric disorders

 Bipolar disorder (manic depressive illness)

 characterized by recurrent mood swings, from euphoric to depressive

 fairly high morbidity and mortality, affects 1-3% of the population

 associated with many other illnesses and substance abuse

 due to changes in the phosphatidylinositol second messenger system



 Acute manic episodes

 elated mood

 hyperactivity

 decreased sleep, attention span

 irritability



 Depression

 feeling of hopeless, helpless, or worthless

 loss of interest or pleasure

 decreased energy, concentration

 changes in appetite, sleep

+

Mechanisms of lithium

in bipolar disorder

Possible mechanisms which have previously been proposed:



Inositol depletion



Decreased GSK-3 activity



Stabilization of cAMP levels



Monoamine Hypothesis on Neurotransmitter Signaling

+

Inositol depletion

 Li+ enters cells as Na+ channel mimic



 Phosphatidylinositol Signaling Cascade:



 inhibits 2 enzymes : Inositol phosphatase converting inositol-2

phosphate to inositol 1 phosphate (IP1), and Inositol phosphatase

converting IP1 to inositol.



 Lithium is thought to inhibit these enzymes by mimicking Mg2+.



 Reduced PIP2 levels while enhancing PIP3



 Downstream, low levels of IP3 and DAG (Diacylglycerol) result in

lowered PKC (Protein Kinase C) activity and Ca2+ release









Schloesser & Huang et al, 2007

+

Decreased glycogen synthase

kinase-3 activity

Glycogen synthase kinase (GSK-3) is a major brain enzyme involved

in:



stabilizing synaptic connections



modulating critical neuronal circuits in brain



Lithium directly inhibits GSK3 by competitive binding N-terminal

active site for Mg2+



not effective on its own



GSK-3 activity is also inhibited INDIRECTLY by Li+



 Li+ upregulates the PI3/Akt pathway



Serine phosphorylation levels of 3(beta) Ser-9 and 3(Alpha) Ser-21



The PP-1/I-2 path inhibition enhances GSK-3 inhibition

+

Inhibition of GSK-3

by lithium









Schloesser & Huang et al, 2007

+

Lithium toxicity

 Lithium toxicity relates to serum concentrations in excess of 1.5

mmol/L which are often very close to therapeutic concentrations

of the drug



 Acute lithium overdose may lead to symptoms of nausea,

vomiting, diarrhea



 Chronic lithium intoxication may lead to symptoms of drowsiness,

muscle twitches, altered mental status, seizures or coma



 To treat lithium toxicity, can reduce dosage, maintain

fluid/electrolyte balance, can use hemodialysis if renal failure

occurs







`



http://www.davita.com/kidney-

disease/dialysis/treatment/what-is-

+

Hypothyroidism

 In this state the thyroid gland does not make enough

thyroid hormone



 Lithium is a goitrogen and may cause goitre by inhibition of

TSH receptor



 Chance of occurence is as high as 15% of patients on long-

term lithium therapy









http://www.webmd.com/a-to-z-guides/thyroid-gland

+

Mechanism of hypothyroidism

caused by lithium Li+









Li+









Li+



Principles of Human Physiology, 2009

+

Drug interactions

Decreases serum Increases serum

concentration of Lithium concentration of Lithium

 Calcitonin  ACE Inhibitors



 Calcium Polystyrene Sulfonate  Angiotensin II Receptor Blockers



 Carbonic Anhydrase Inhibitors  Nonsteroidal Anti-Inflammatory



 Sodium Polystyrene Sulfonate  Sodium Bicarbonate



 Theophylline Derivatives  Sodium Chloride



 Thiazide Diuretics  Topiramate



 Sodium Bicarbonate  Desmopressin



 Sodium Chloride  Loop Diuretics*



 Antipsychotics  Calcium Channel Blockers*



 Loop Diuretics*  Abrupt withdrawal of caffeine (24%)



 Calcium Channel Blockers

+

Drugs that enhance the adverse

or toxic effects of lithium

 CarBAMazepine



 Calcium Channel Blockers

Drug Adverse

 Fosphenytoin Effects/

Lithium Side

 MAO Inhibitors Effects



 Methyldopa



 Phenytoin



 Potassium Iodide



 Selective Serotonin Reuptake Inhibitors

+

Lithium enhances the adverse

or toxic effects of these drugs

 Amphetamines



 Antipsychotics

Lithium Adverse

 Desmopressin Effects/

Drug Side

 Sibutramine Effects



 Serotonin Modulators



 Neuromuscular-Blocking Agents



 Tricyclic Antidepressants

+

Summary

 Lithium is a mood-stabilizing drug with anti-suicidal properties used for treatment of bipolar disorder,

depression, and chronic cluster headache.



 It generally effective, but its use is controversial due to its narrow therapeutic window, many serious toxic effects,

and numerous food and drug interactions.



 Lithium directly and indirectly inhibits a major enzyme GSK-3 known to have long-term changes in stabilizing

synaptic connections and modulating critical neuronal circuits in brain.



 Lithium mimics Mg2+ and disrupts the phosphatidylinositol signalling cascade by competitive inhibition of

inositol phosphatase enzymes, which depletes inositol levels and blocks the regeneration of PIP2.



 Low levels of IP3 and DAG leads to low PKC activity and Ca2+ release in the cell.



 Lithium toxicity may occur with overdose of the drug or occasionally even at therapeutic concentrations.



 This leads to common symptoms for acute toxicity like nausea and vomiting, or symptoms of chronic toxicity such

as drowsiness and muscle spasms.



 One adverse effect, hypothyroidism, is caused by inhibition in the thyroid hormone production pathway.



 Abruptly decreasing the ingestion of caffeine will increase the serum concentration of lithium.



 Multiple drugs have the capabilities to either increase or decrease the serum concentration of lithium, therefore,

lithium doses needs to be altered based on the effects of these drugs.

+

References



 Borsotto M, et al (2007): PP2A-Bgamma subunit and KCNQ2 K+ channels in bipolar

disorder. Pharmacogenomics Journal (2):123-32.



 Frost RE, Messiha FS. (1983) Clinical Uses of Lithium Salts. Brain Res. Bull. 11(2):219-231.



 Livingstone, C., & Rampes, H. (2006). Lithium: a review of its metabolic adverse effects. J.

of Psychopharmacology, 20(3), 347-355. Retrieved from http://tinyurl.com/cke3g96



 Marmol F. (2008) Lithium: Bipolar disorder and neurodegenerative diseases Possible

cellular mechanisms of the therapeutic effects of lithium. Progress in

Neuropsychopharmacology & Bio. Psy. 32(8):1761-1771.



 Mester R, Toren P, Mizrachi I, Wolmer L, Karni N, Weizman A. (1995) Caffeine Withdrawal

Increases Lithium Blood Levels. Biol Psychiatry 37:348-350.



 O'Brien W. T. and. Klein P. S. (2009) Validating GSK3 as an in vivo target of lithium action.

Biochem Soc Trans. Vol 37( 5): 1133–1138.

+

References



 Repchinsky, C., Welbanks, L., Hutsul, J., Jovaisas, B., & Lewis, G. (Eds.) (2011). Cps 2011,

compendium pharmaceuticals and specialties. (46 ed.). Canadian Pharmacist

Association. Retrieved from https://www-e-therapeutics-

ca.myaccess.library.utoronto.ca/cps.showMonograph.action?newSearch=true&simpleI

ndex=BrandGeneric&simpleQuery=lithium



 Rybakowski J. (2011) Lithium in neuropsychiatry: A 2010 update. World J. Biol.

Psychiatry. 12(5):340-348.



 Savarese, D. M., and Zand, J. M. (2011) Lithium: Drug information. Retrieved

fromhttp://www.uptodate.com.proxy1.lib.uwo.ca:2048/contents/lithium-drug-

information?source=search_result&search=Lithium&selectedTitle=1~150



 Schloesser R.J, Huang J, Klein P.S, and Manji H. K. (2007) Cellular Plasticity Cascades in

the Pathophysiology and Treatment of Bipolar Disorder. Neuropsychopharmacology.

(33): 110-133.



 Stanfield, C. L., & Germann, W. J. (2009). Principles of human physiology. (3 ed.). San

Francisco: Benjamin-Cummings Pub Co.



Related docs
Other docs by Jun Wang
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!